Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:ERJ Open Res
Hoofdauteurs: Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: European Respiratory Society 2021
Onderwerpen:
Study Protocols
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/
https://ncbi.nlm.nih.gov/pubmed/34164554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items